# Sinovac (Dalian) Vaccine Technology trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Sinovac (Dalian) Vaccine Technology Co., Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sinovac (Dalian) Vaccine Technology Co., Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/sinovac-dalian-vaccine-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 16, 2026 | NCT07475000 | Second Dose of Varicella Vaccine in Healthy Children | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Recruiting | Varicella (Chickenpox), Varicella Immunisation | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475000) |
| March 16, 2026 | NCT07473427 | Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Not yet recruiting | Varicella (Chickenpox), Varicella Immunisation | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473427) |
| May 29, 2025 | NCT06994052 | Study on Booster Immunization With Varicella Vaccine at Different Intervals | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Completed | VZV, Varicella Immunisation | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994052) |
| May 23, 2025 | NCT06987942 | Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Completed | Varicella, Influenza Vaccine | 899 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987942) |
| March 24, 2025 | NCT06891872 | Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Not yet recruiting | Varicella (chickenpox), MMR Vaccine, DTaP Vaccine | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06891872) |
| July 3, 2024 | NCT06484686 | An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Enrolling by invitation | Varicella | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06484686) |
| July 1, 2024 | NCT06482216 | Correlation of Protection Against Varicella in an Exploratory Study | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Observational | Not yet recruiting | Varicella | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482216) |
| March 18, 2024 | NCT06314724 | Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Completed | Varicella | 642 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06314724) |
| September 2, 2022 | NCT05526820 | A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Completed | Varicella | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526820) |
| July 22, 2022 | NCT05470855 | Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Unknown | Varicella | 45,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470855) |
| July 15, 2022 | NCT05460429 | Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella... | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Unknown | Varicella | 37,920 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05460429) |
| December 9, 2021 | NCT05150392 | An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and... | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Completed | Varicella | 1,193 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05150392) |
| December 6, 2021 | NCT05145166 | Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Observational | Completed | Mumps | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05145166) |
| October 27, 2021 | NCT05095701 | An Immunity Persistence Study of Live Attenuated Varicella Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Enrolling by invitation | Varicella | 703 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05095701) |
| August 20, 2021 | NCT05015686 | Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Unknown | Varicella | 2,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05015686) |
| April 28, 2020 | NCT04364399 | Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 | Completed | Mumps | 920 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04364399) |
| June 13, 2018 | NCT03555071 | A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Completed | Varicella | 1,197 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03555071) |
| December 5, 2016 | NCT02981836 | A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Completed | Varicella | 5,997 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02981836) |
| November 16, 2016 | NCT02965404 | A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 1 | Completed | Varicella | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02965404) |
| February 26, 2016 | NCT02692599 | Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 | Completed | Mumps | 1,150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02692599) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 3 | 8 |
| Phase 4 | 9 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Unknown | 3 |
| Not yet recruiting | 3 |
| Enrolling by invitation | 2 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Chickenpox | 16 |
| Mumps | 3 |
| Measles | 1 |
| Influenza, Human | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Eastern European restaurants in the United States](https://specstream.ai/data/businesses/eastern-european-restaurants/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Skylight installation companies in the United States](https://specstream.ai/data/businesses/skylight-installation-companies/united-states)
- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
